On this resource, the following formatting is used for comprehensiveness:
- Minimal depth
- (Moderate depth)
As per presentation above.
Medical imaging provides a major clue as to whether a lung tumor is benign or malignant, where lesions smaller than 2 cm are likely to be benign, whereas lesions larger than 2 cm are malignant (that is, lung cancer) in 85% of cases.
Subsequently distribution of benign tumors and lung cancers, respectively, are as follows:
Benign lung tumors:
- Hamartomas - 76%
- Benign fibrous mesothelioma/solitary fibrous tumor (SFT) - 12.3%
- Inflammatory pseudotumor (IPT) - 5.4%
- Lipoma - 1.5%
- Leiomyoma - 1.5%
- Other - 3.3%
Lung adenocarcinoma, with lepidic pattern shown, wherein tumors cells cover alveolar walls.
Lung adenocarcinoma, with solid pattern.
For non-small cell carcinoma, the following algorithm can be applied:
- Stages IB through IIIA: EGFR mutation analysis.
- Stages IIIB and IV: Full next generation sequencing panel (DNA and RNA) with PDL-1 immunostaining.
- Alain C. Borczuk (2008). "Benign Tumors and Tumorlike Conditions of the Lung ". Archives of Pathology & Laboratory Medicine 132 (7). Archived from the original. .
- Kuroki, Masaomi; Nakata, Hiroshi; Masuda, Toshifumi; Hashiguchi, Norihisa; Tamura, Shozo; Nabeshima, Kazuki; Matsuzaki, Yasunori; Onitsuka, Toshio (2002). "Minute Pulmonary Meningothelial-like Nodules: High-Resolution Computed Tomography and Pathologic Correlations ". Journal of Thoracic Imaging 17 (3): 227–229. doi:10.1097/00005382-200207000-00008. ISSN 0883-5993.
- Image by: Mikael Häggström, M.D. Public Domain
- Author info
- Reusing images
- Dr Nicholas Turnbull, A/Prof Patrick Emanual (2014-05-03). Squamous cell carcinoma pathology. DermNetz.